2,743
Views
4
CrossRef citations to date
0
Altmetric
Commentary

Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?

ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon & show all
Pages 495-499 | Received 11 Sep 2017, Accepted 01 Nov 2017, Published online: 21 Dec 2017

References

  • Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World Health Organization-Coordinated Global Rotavirus Surveillance N. Global, Regional, and National Estimates of rotavirus mortality in Children <5 Years of Age, 2000–2013. Clin Infect Dis. 2016;62(Suppl 2):S96–S105. doi:10.1093/cid/civ1013. PMID:27059362.
  • Rotavirus vaccines. WHO position paper- January 2013. Wkly Epidemiol Rec. 2013;88:49–64. PMID:23424730.
  • Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis. 2013;208(2):284–94. doi:10.1093/infdis/jit166. PMID:23596320.
  • Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of Rotavirus Vaccination: A systematic review of the first decade of global post-licensure data, 2006–2016. Clin Infect Dis. 2017;65(5):840–850. doi:10.1093/cid/cix369. PMID: 28444323
  • Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012;11:CD008521. doi:10.1002/14651858.CD008521.pub3.
  • Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565–72. doi:10.3201/eid0905.020562. PMID:12737740.
  • Santos VS, Marques DP, Martins-Filho PR, Cuevas LE, Gurgel RQ. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infectious Diseases of Poverty. 2016;5(1):83. doi:10.1186/s40249-016-0173-2. PMID:27514855.
  • Parashar UD, Johnson H, Steele AD, Tate JE. Health impact of rotavirus vaccination in developing countries: Progress and way forward. Clin Infect Dis. 2016;62 Suppl 2:S91–5. doi:10.1093/cid/civ1015. PMID:27059361.
  • Kirkwood CD, Steele AD. Rotavirus vaccine will have an impact in Asia. PLoS Med. 2017;14(5):e1002298. doi:10.1371/journal.pmed.1002298. PMID:28486524.
  • Zaman K, Sack DA, Neuzil KM, Yunus M, Moulton LH, Sugimoto JD, et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med. 2017;14(4):e1002282. doi:10.1371/journal.pmed.1002282. PMID:28419095.
  • Lopez AL, Raguindin PF, Esparagoza J, Fox K, Castro M, Parashar U, et al. Impact of rotavirus vaccine introduction in Agusan Del Sur, Philippines. Twelfth International Rotavirus Symposium; 7 – 9 September 2016; Melbourne, Australia; 2016.
  • Rota council. Rotavirus: common, severe, devastating, preventable. http://rotacouncil.org/wp-content/uploads/2016/11/Rotavirus-Severe-Preventable-White-Paper-Full.pdf Accessed 5 October 2017.
  • Kallenberg J, Mok W, Newman R, Nguyen A, Ryckman T, Saxenian H, et al. Gavi's transition policy: Moving from development assistance to domestic financing of immunization programs. Health Affairs. 2016;35(2):250–8. doi:10.1377/hlthaff.2015.1079. PMID:26858377.
  • Simpson E, Wittet S, Bonilla J, Gamazina K, Cooley L, Winkler JL. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health. 2007;7:281. doi:10.1186/1471-2458-7-281. PMID:17919334.
  • Bill and Melinda Gates Foundation. Currently available vaccines and introduction status. http://rotacouncil.org/wp-content/uploads/2017/05/Singapore-Slides-Carey-Final.pdf Accessed 5 October 2017.
  • Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–43. doi:10.1016/S0140-6736(13)62630-6. PMID:24629994.
  • Arora R, Swaminathan S. Ready to measure impact? The introduction of Rotavirus Vaccine in India. Indian Pediatr. 2016;53:565–7. doi:10.1007/s13312-016-0889-x. PMID:27508530.
  • Isanaka S, Guindo O, Langendorf C, Seck AM, Plikaytis BD, Sayinzoga-Makombe N, et al. Efficacy of a lowcost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med. 2017;376:1121–30. doi:10.1056/NEJMoa1609462. PMID:28328346.
  • Bai ZS, Chen DM, Shen S. [Selection and characterization of strain LLR- 85 for oral rotavirus live vaccine] Chinese. Zhong Guo Sheng Wu Zhi Ping Xue Za Zi. 1994;7:46–52.
  • Zhen SS, Li Y, Wang SM, Zhang XJ, Hao ZY, Chen Y, et al. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerging Microbes & Infections. 2015;4(10):e64. doi:10.1038/emi.2015.64.
  • Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, et al. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine. 2012;30 Suppl 1:A114–21. PMID:22520120.
  • Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA, et al. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine. 2013;31(23):2610–6. doi:10.1016/j.vaccine.2013.04.008. PMID:23597719.
  • Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2015;15(12):1389–97. doi:10.1016/S1473-3099(15)00227-3. PMID:26318715.
  • Luna EJ, Frazatti-Gallina NM, Timenetsky MC, Cardoso MR, Veras MA, Miraglia JL, et al. A phase I clinical trial of a new 5-valent rotavirus vaccine. Vaccine. 2013;31(7):1100–5. doi:10.1016/j.vaccine.2012.12.020. PMID:23261048.
  • Dhingra MS, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh MP, et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014;32 Suppl 1:A117–23. doi:10.1016/j.vaccine.2014.03.069. PMID:25091664.
  • PATH. Phase I/II Descending Age Study of P2VP8 subunit parenteral rotavirus vaccine in Healthy Toddlers and Infants 2014 [Available from: https://clinicaltrials.gov/ct2/show/NCT02109484.
  • Naik SP, Zade JK, Sabale RN, Pisal SS, Menon R, Bankar SG, et al. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL(R)). Vaccine. 2017;35(22):2962–9. doi:10.1016/j.vaccine.2017.04.025. PMID:28434688.
  • Steele AD, Madhi SA, Cunliffe NA, Vesikari T, Phua KB, Lim FS, et al. Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination. Human Vaccines & Immunotherapeutics. 2016;12(9):2406–2412. doi:10.1080/21645515.2016.1179412.
  • Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med. 2011;365(4):337–46. doi:10.1056/NEJMoa1006261. PMID:21793745.
  • Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, Aaby P, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis. 2002;186(5):593–7. doi:10.1086/342294. PMID:12195345.
  • Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335(14):1022–8. doi:10.1056/NEJM199610033351404. PMID:8793926.
  • Page AL, Jusot V, Mamaty AA, Adamou L, Kaplon J, Pothier P, et al. Rotavirus surveillance in urban and rural areas of Niger, April 2010-March 2012. Emerg Infect Dis. 2014;20(4):573–80. doi:10.3201/eid2004.131328. PMID:24655441.
  • Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362(4):289–98. doi:10.1056/NEJMoa0904797. PMID:20107214.
  • Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30 Suppl 1:A24–9. doi:10.1016/j.vaccine.2011.08.124. PMID:22520132.
  • Bharat Biotech rolls out a low-cost vaccine against Rotavirus Diarrhoea. https://indiabioscience.org/news/2013/bharat-biotech-rolls-out-a-low-cost-vaccine-against-rotavirus-diarrhoea Accessed 23 January 2017
  • Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC Infect Dis. 2016;16(1):677. doi:10.1186/s12879-016-2013-1. PMID:27846803.
  • Vietnam produces diarrhoea vaccine. http://baodongnai.com.vn/english/health/201402/vietnam-produces-diarrhoea-vaccine-2294722/. Accessed 30 April 2017